Aims
Yimitasvir is a novel, oral hepatitis C virus (HCV) non-structural
protein 5A inhibitor for the treatment of chronic HCV genotype 1
infection. The objective of this analysis was to develop a population
pharmacokinetic model of yimitasvir in Chinese healthy volunteers and
HCV infection patients.